We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cardiac Biomarker Assesses Heart Failure Prognosis

By LabMedica International staff writers
Posted on 02 Feb 2011
The levels of cardiac biomarkers in blood plasma predict the outcome for ambulatory outpatients with chronic heart failure and they more effectively risk-stratify such patients.

An assay to measure the amount of soluble growth stimulation expressed gene 2 protein (ST2) has been used to identify heart failure patients who are significantly more likely to have a heart transplant or to die during the three-year follow-up period.

In a multicenter cohort study, 1,141 heart failure patients were recruited from three tertiary-care centers, and were followed for a median of 2.8 years. More...
ST2 levels were measured at baseline from a blood sample taken at the enrollment of each patient into the study. The investigators conducted statistical analyses to predict outcomes by examining clinical presentation as well as the cardiac biomarkers ST2 and N-terminal brain natriuretic peptide (NT-proBNP).

The test used was the Presage ST2 Assay (Critical Diagnostics, San Diego, CA, USA). There were 267 (23% of patients) adverse events over the period, defined as the combined endpoint of death or cardiac transplantation. Patients in the highest ST2 tertile with levels above 36.3 ng/mL, had a markedly increased risk of adverse outcomes compared to the lowest tertile whose ST2 levels were equal to or less than 22.3 ng/mL. The unadjusted hazard ratio (HR) of 3.2 remained significant after multivariable adjustment; adjusted HR equaled 1.9. With each doubling of ST2, there was a 40% to 50% increased risk of death or cardiac transplantation in fully adjusted models.

Soluble ST2 reflects activity of an interleukin (IL-33) dependent cardioprotective signaling axis and is a diagnostic and prognostic marker in acute heart failure. ST2 signals the presence of adverse cardiac remodeling and fibrosis, which occurs in response to myocardial infarction (MI), ischemia, or worsening heart failure. Remodeling and fibrosis can also contribute to the development of future adverse events, such as secondary MI or sudden cardiac death, and to progression of heart failure.

Patrick A. Arensdorf, B.A., M.B.A., CEO of Critical Diagnostics, said, "The study found that more than one in seven chronic heart failure patients can be more appropriately risk-stratified when using ST2 and NT-proBNP in addition to the Seattle Heart Failure Model. By using the Presage ST2 Assay, clinicians may be able to target heart failure therapy more appropriately.” The study was published as an advance e-publication of the January 19, 2010 edition of Circulation: Heart Failure.

Related Links:
Critical Diagnostics



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.